Novo Nordisk Company Analysis

Novo Nordisk is a global healthcare company that discovers, develops, and manufactures pharmaceutical products. It primarily focuses on medications for diabetes and obesity, alongside treatments for rare blood and endocrine disorders.

Novo Nordisk reported strong Q3 2026 financial results, with adjusted sales reaching DKK 79.20 billion and adjusted operating profit rising 27% to DKK 31.72 billion at constant exchange rates. The company raised its full-year 2026 outlook to between 2% growth and a 2% decline, up from previous estimates. The Wegovy pill generated DKK 5.39 billion in Q3 2026, up 53% sequentially.

Context: Eli Lilly has gained significant traction with its competing obesity drugs, capturing a large share of the injectable market. Novo Nordisk maintains a dominant position in the oral obesity drug market, with its Wegovy pill holding an estimated 80% of new-to-brand prescriptions in the US. The company is aggressively defending its market share through faster rollouts, strategic acquisitions like Akero Therapeutics, and expanding indications.

Novo Nordisk has a strong historical reputation for sustainability and corporate responsibility, deeply integrated into its foundation-led governance structure.

29 accepted sources (25 pages from 7 domains, 4 search results), 19 official items.